Skip to main content
. 2023 Jan 20;18(1):e0276423. doi: 10.1371/journal.pone.0276423

Fig 1. Lower HbA1cs are observed in Type 1, but not Type 2, diabetic subjects post-BCG treatment for bladder cancer.

Fig 1

For T1Ds, all three datasets (MSA, RPDR and OL) show a reduction in HbA1c, calculated as percentage change in HbA1c values post-BCG instillation. Each dataset also shows a near 10% decrease in HbA1cs at differing time points. Combined, the data for T1Ds convey a statistically significant decrease in year 1 post-BCG instillation (p = 0.0304). In contrast, the MSA data for T2Ds show no change in the HbA1cs of patients, and the RPDR reveals an increase in HbA1c values post-BCG instillation. The combined data shows no significant change. N’s for each dataset: RPDR = 4, MSA = 9 and OL = 6 for T1Ds. And RPDR = 97, MSA = 9 for T2Ds.